[go: up one dir, main page]

US20190217531A1 - Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object - Google Patents

Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object Download PDF

Info

Publication number
US20190217531A1
US20190217531A1 US16/088,041 US201716088041A US2019217531A1 US 20190217531 A1 US20190217531 A1 US 20190217531A1 US 201716088041 A US201716088041 A US 201716088041A US 2019217531 A1 US2019217531 A1 US 2019217531A1
Authority
US
United States
Prior art keywords
molded object
water
dimensionally molded
eluting
fast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/088,041
Other languages
English (en)
Inventor
Sorato Ikeda
Shota Hattori
Masanori Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Assigned to ASTELLAS PHARMA INC. reassignment ASTELLAS PHARMA INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Hattori, Shota, IKEDA, Sorato, KOBAYASHI, MASANORI
Publication of US20190217531A1 publication Critical patent/US20190217531A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/10—Processes of additive manufacturing
    • B29C64/106—Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
    • B29C64/118—Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00—Materials specially adapted for additive manufacturing
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/15—Heterocyclic compounds having oxygen in the ring
    • C08K5/151—Heterocyclic compounds having oxygen in the ring having one oxygen atom in the ring
    • C08K5/1545—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L29/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers
    • C08L29/02—Homopolymers or copolymers of unsaturated alcohols
    • C08L29/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L39/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions of derivatives of such polymers
    • C08L39/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
    • C08L39/06—Homopolymers or copolymers of N-vinyl-pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2029/00—Use of polyvinylalcohols, polyvinylethers, polyvinylaldehydes, polyvinylketones or polyvinylketals or derivatives thereof as moulding material
    • B29K2029/04—PVOH, i.e. polyvinyl alcohol
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00—Use of polymers of unsaturated acids or derivatives thereof as moulding material
    • B29K2033/04—Polymers of esters
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2039/00—Use of polymers with unsaturated aliphatic radicals and with a nitrogen or a heterocyclic ring containing nitrogen in a side chain or derivatives thereof as moulding material
    • B29K2039/06—Polymers of N-vinyl-pyrrolidones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing

Definitions

  • the present invention relates to a fast-eluting three-dimensionally molded object, a filament for fast-eluting three-dimensionally molded object, and a material for fast-eluting three-dimensionally molded object.
  • the present invention relates to a fast-eluting three-dimensionally molded object formed by fused deposition modeling type three-dimensional molding, a filament for fast-eluting three-dimensionally molded object for the fused deposition modeling, and a material for fast-eluting three-dimensionally molded object for the fused deposition modeling.
  • the 3D printing technique can be classified into a plurality of groups mainly in accordance with a difference in a type of lamination.
  • Examples of the 3D printing technique includes fused deposition modeling (FDM) in which a thermoplastic resin serving as a material for three-dimensionally molded object is thermally melted, extruded from a nozzle, and molded while being laminated on a molding stage and powder bed printing in which a powdery resin serving as a material for three-dimensionally molded object is laid over a molding stage and then a binder is sprayed on the powdery resin.
  • FDM fused deposition modeling
  • Other techniques include stereolithography, powder selective laser sintering, and the like.
  • Patent literature 1 discloses a material that develops little warpage and is easily subjected to surface polishing. It is disclosed that using such a material is advantageous for producing an industrial part having a new shape, confirming a design in a pre-production stage, and the like.
  • levetiracetam produced in a solid form using a 3D printer has been approved as a drug product under a name of SPRITAM (registered trademark) by U.S. Food and Drug Administration (FDA).
  • SPRITAM registered trademark
  • FDA U.S. Food and Drug Administration
  • Non patent literature 1 discloses an extended-release patient-tailored prednisolone tablet produced by the fused deposition modeling type three-dimensional molding.
  • the prednisolone tablet includes a water-soluble thermoplastic polymer (a polyvinyl alcohol) as a base and has an elution rate of prednisolone serving as a pharmaceutically active component of 80% or higher in about 8 to 18 hours.
  • a water-soluble thermoplastic polymer a polyvinyl alcohol
  • Non patent literature 2 discloses a tablet that is produced by the fused deposition modeling type three-dimensional molding and allows an adjustment of a drug dose.
  • the tablet includes a polyvinyl alcohol as abase and has an elution rate of fluorescein serving as a model drug of 80% or higher in about 4.5 to 9 hours.
  • Non patent literature 3 discloses a tablet that is produced by the fused deposition modeling type three-dimensional molding and includes 4-aminosalicylic acid or 5-aminosalicylic acid in a modified-release formulation.
  • the tablet includes a polyvinyl alcohol as a base and has an elution rate of 5-aminosalicylic acid of 80% or higher in about 1.5 to 2.5 hours.
  • the fused deposition modeling and the powder bed printing are adopted to produce a solid object (a three-dimensionally molded object) using the 3D printer.
  • the strength of the three-dimensionally molded object becomes relatively weak, thereby causing a risk of breakage of the solid object, such as cracking and chipping, during a distribution process.
  • the fused deposition modeling is adopted, the solid object hardly collapses, thereby causing a problem of reducing an elution rate of an active component.
  • the present invention is made in light of the above-mentioned problems, and an object of the present invention is to provide a fast-eluting three-dimensionally molded object, which is formed by fused deposition modeling type three-dimensional molding and quickly elutes an active component.
  • another object of the present invention is to provide a filament for fast-eluting three-dimensionally molded object and a material for fast-eluting three-dimensionally molded object used for forming the fast-eluting three-dimensionally molded object by the fused deposition modeling type three-dimensional molding.
  • another object of the present invention is to provide the fast-eluting three-dimensionally molded object, the filament for fast-eluting three-dimensionally molded object, and the material for fast-eluting three-dimensionally molded object, which exhibit excellent injection moldability and printability in performing the three-dimensional molding by the fused deposition modeling.
  • the present inventors have conducted intensive studies and found that a three-dimensionally molded object that elutes an active component relatively quickly can be produced when a material for three-dimensionally molded object used for the fused deposition modeling type three-dimensional molding includes the active component, a water-soluble thermoplastic polymer, a water-soluble sugar and/or a water-soluble sugar alcohol, and a plasticizer component, thereby completing the present invention.
  • the present inventors have found that the material for three-dimensionally molded object exhibits excellent injection moldability in producing the filament for three-dimensionally molded object and excellent printability in performing the three-dimensional molding by the fused deposition modeling, thereby completing the present invention.
  • a three-dimensionally molded object which is formed by fused deposition modeling type three-dimensional molding and includes an active component, a water-soluble thermoplastic polymer, a water-soluble sugar and/or a water-soluble sugar alcohol, and a plasticizer component.
  • the three-dimensionally molded object that exhibits excellent injection moldability and printability can be achieve by performing the three-dimensional molding by the fused deposition modeling.
  • an elution rate of the active component by a paddle method of a dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition is preferably 80% or higher within 85 minutes.
  • the water-soluble sugar and/or the water-soluble sugar alcohol has a glass transition temperature of preferably a room temperature or higher.
  • the water-soluble sugar and/or the water-soluble sugar alcohol is further preferably one or more kinds selected from the group consisting of sucrose, maltitol, xylitol, mannitol, erythritol, sorbitol, isomalt, and lactitol.
  • the water-soluble sugar and/or the water-soluble sugar alcohol is preferably one or more kinds selected from the group consisting of maltitol, xylitol, mannitol, erythritol, sorbitol, isomalt, and lactitol.
  • the water-soluble thermoplastic polymer is preferably one or more kinds selected from the group consisting of a polyvinyl alcohol, a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyethylene oxide, polyvinylpyrrolidone, copolyvidone, a polyethylene glycol-polyvinyl alcohol-graft copolymer, a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, aminoalkyl methacrylate copolymer RS, and aminoalkyl methacrylate copolymer E.
  • a polyvinyl alcohol a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer
  • polyethylene oxide polyvinylpyrrolidone, copolyvidone
  • a polyethylene glycol-polyvinyl alcohol-graft copolymer a polyvinyl alcohol-acrylic acid-methyl meth
  • the water-soluble thermoplastic polymer is preferably one or more kinds selected from the group consisting of a polyvinyl alcohol, polyvinylpyrrolidone, and aminoalkyl methacrylate copolymer E.
  • the water-soluble thermoplastic polymer is one or more kinds selected from the group consisting of a polyvinyl alcohol, polyvinylpyrrolidone, and aminoalkyl methacrylate copolymer E and the water-soluble sugar and/or the water-soluble sugar alcohol is maltitol.
  • the content of the water-soluble sugar and/or the water-soluble sugar alcohol is preferably 10 to 65 wt. % with respect to the total weight of the three-dimensionally molded object.
  • the content of the water-soluble thermoplastic polymer is preferably 20 to 90 wt. % with respect to the total weight of the three-dimensionally molded object.
  • the water-soluble thermoplastic polymer the water-soluble sugar and/or the water-soluble sugar alcohol, and the plasticizer component, optimizing each of these materials and the content thereof as described above can impart further excellent injection moldability and printability and achieve the three-dimensionally molded object adjustable to further increase the elution rate of the active component.
  • the elution rate of the active component is preferably 80% or higher within 30 minutes.
  • the three-dimensionally molded object is preferably a ring-shaped solid object.
  • a filament for fast-eluting three-dimensionally molded object and a material for fast-eluting three-dimensionally molded object used for forming a three-dimensionally molded object by fused deposition modeling type three-dimensional molding can be achieved by including an active component, a water-soluble thermoplastic polymer, a water-soluble sugar and/or a water-soluble sugar alcohol, and a plasticizer component.
  • the fast-eluting three-dimensionally molded object which is formed by the fused deposition modeling type three-dimensional molding and quickly elutes the active component.
  • the filament for fast-eluting three-dimensionally molded object and the material for fast-eluting three-dimensionally molded object used for forming the fast-eluting three-dimensionally molded object by the fused deposition modeling type three-dimensional molding can be provided.
  • the fast-eluting three-dimensionally molded object, the filament for fast-eluting three-dimensionally molded object, and the material for fast-eluting three-dimensionally molded object which exhibit excellent injection moldability and printability in performing the three-dimensional molding by the fused deposition modeling.
  • FIG. 1 is result data of an elution test in Test example
  • FIG. 2A is a perspective view illustrating a solid object (in a cylinder shape) in Example 2-1.
  • FIG. 2B is a perspective view illustrating a solid object (in a ring shape 1 ) in Example 2-2.
  • FIG. 2C is a perspective view illustrating a solid object (in a ring shape 2 ) in Example 2-3.
  • FIG. 3 is result data of the elution test using the solid objects having different shapes in Test example 2.
  • FIG. 4 is result data of the elution test in Test example
  • FIG. 5 is result data of an oral absorbability test in a dog in Test example 4.
  • FIG. 6 is result data of the elution test in Test example
  • FIG. 7 is result data of the elution test in Test example
  • FIG. 8 is result data of the elution test in Test example
  • FIG. 9 is result data of the elution test in Test example
  • FIG. 10 is result data of the elution test in Test example
  • FIG. 11 is result data of the elution test in Test example
  • the present embodiments relate to the invention of a fast-eluting three-dimensionally molded object, which is formed by fused deposition modeling type three-dimensional molding and characterized by including a pharmaceutically active component, a polyvinyl alcohol, maltitol, and triethyl citrate.
  • the present embodiments relate to the invention of a filament for fast-eluting three-dimensionally molded object and a material for fast-eluting three-dimensionally molded object used for forming the fast-eluting three-dimensionally molded object described above.
  • material for three-dimensionally molded object refers to a fast-eluting material, which is suitably used for the three-dimensional molding, in particular, for the fused deposition modeling, and includes a component that can be used for oral administration, oral ingestion, intraoral administration, intrarectal administration, or vaginal administration.
  • the material for three-dimensionally molded object is, for example, formed in a powder shape and obtained by appropriately formulating each constituent component, however, the shape can be changed without a particular limitation.
  • the powder obtained by formulating each constituent component maybe granulated to form a pellet.
  • filament for three-dimensionally molded object refers to a product obtained by subjecting the material for three-dimensionally molded object to melt-kneading with compression and extrusion molding using an extruding machine (an extruder) or the like.
  • the filament for three-dimensionally molded object is formed, for example, as a filamentous body having a diameter of about 1.0 to 3.0 mm.
  • three-dimensionally molded object refers to a product obtained by thermally melting the filament for three-dimensionally molded object, extruding the melted filament from a nozzle, and molding the melted filament layer by layer on a molding stage using a fused deposition modeling type 3D printing apparatus.
  • An administration route of the three-dimensionally molded object is not particularly limited.
  • Examples of the administration route include oral administration or oral ingestion, intraoral administration, intrarectal administration, vaginal administration, and the like. Oral administration is preferable.
  • the three-dimensionally molded object is not limited to a pharmaceutical and may be, for example, a solid food for oral ingestion, such as a food for specified health uses, a food with nutrient function claims, a food with function claims, and a supplement.
  • the three-dimensionally molded object is preferably formed in a ring shape. However, the shape may be changed without a particular limitation.
  • the three-dimensionally molded object may be formed in a conventional cylinder or elliptical shape.
  • the material for three-dimensionally molded object includes an active component, a water-soluble thermoplastic polymer, a water-soluble sugar and/or a water-soluble sugar alcohol, and a plasticizer component.
  • the material for three-dimensionally molded object may further include various additive components.
  • a binder a stabilizer, a disintegrating agent, a disintegrating assistant, an acidulant, a foaming agent, an artificial sweetener, a flavoring agent, a lubricant, a coloring agent, a buffer, an antioxidant, a surfactant, and the like may be combined and suitably included in an appropriate amount.
  • the term “active component” refers to a material that exhibits physiological activity included in a pharmaceutical agent, a quasi-drug, a health food, and the like.
  • the active component serving as an active component of the three-dimensionally molded object is not particularly limited as long as it is stable after thermally melted.
  • the active component maybe a pharmaceutical.
  • the active component may be the one included in a food for specified health uses, a food with nutrient function claims, a food with function claims, a supplement, and the like.
  • the pharmaceutically active component used as the active component is preferably poorly water soluble.
  • the pharmaceutically active component is not particularly limited to the one described above, and may be water insoluble or water soluble.
  • the pharmaceutically active component may be an active component included in a food for specified health uses, a food with nutrient function claims, a food with function claims, a supplement, and the like.
  • the content of the active component of the material for three-dimensionally molded object is 0.1 to 40 wt. %, preferably 0.1 to 20 wt. %, with respect to the total weight of the material for three-dimensionally molded object (the filament for three-dimensionally molded object, the three-dimensionally molded object).
  • the content may be changed without a particular limitation within a range capable of achieving the effect of the present invention.
  • thermoplastic polymer refers to a polymer material which has thermoplasticity, that is, a property causing a material to be hardly deformable at a normal temperature, but freely deformable due to plasticity upon appropriate heating and rigid again upon cooling.
  • the thermoplastic polymer serves as a base of the three-dimensionally molded object and imparts excellent injection moldability and printability (plasticity).
  • the thermoplastic polymer is preferably water soluble in order to increase elutability of the active component into water.
  • thermoplastic polymer is preferably one or more kinds selected from the group consisting of a polyvinyl alcohol, a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyethylene oxide, polyvinylpyrrolidone, copolyvidone, a polyethylene glycol-polyvinyl alcohol-graft copolymer, a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, aminoalkyl methacrylate copolymer RS, and aminoalkyl methacrylate copolymer E.
  • a polyvinyl alcohol a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer
  • polyethylene oxide polyvinylpyrrolidone, copolyvidone
  • a polyethylene glycol-polyvinyl alcohol-graft copolymer a polyvinyl alcohol-acrylic acid-methyl methacrylate copo
  • the thermoplastic polymer may be one or more kinds selected from the group consisting of a polyvinyl alcohol, polyvinylpyrrolidone, a polyethylene glycol-polyvinyl alcohol-graft copolymer, and aminoalkyl methacrylate copolymer E.
  • the thermoplastic polymer is preferably one or more kinds selected from the group consisting of a polyvinyl alcohol, polyvinylpyrrolidone, and aminoalkyl methacrylate copolymer E.
  • the polyvinyl alcohol is more preferable from the viewpoint of printability.
  • thermoplastic polymer allows the preparation of the filament having high plasticity and more strength.
  • the polyvinyl alcohol is preferably a polymer compound that has high water solubility, a relatively small average molecular weight (average polymerization degree), and a relatively small saponification rate.
  • the polyvinyl alcohol has the average molecular weight of 20,000 (the average polymerization degree of 400) or less, preferably 10, 000 (the average polymerization degree of 200) or less, more preferably 6,000 (the average polymerization degree of 120) or less. Further, the polyvinyl alcohol has the saponification rate of 90.0 mol % or less, preferably 80.0 mol % or less.
  • the content of the water-soluble thermoplastic polymer is 20 to 90 wt. %, preferably 20 to 80 wt. %, more preferably 20 to 40 wt. %, with respect to the total weight of the material for three-dimensionally molded object (the filament for three-dimensionally molded object, the three-dimensionally molded object).
  • the content may be changed without a particular limitation within a range capable of achieving the effect of the present invention.
  • water-soluble sugar and/or water-soluble sugar alcohol refers to a component that imparts excellent plasticity, improves injection moldability and printability, increases elutability of the active component into water, and the like.
  • the sugar alcohol that hardly causes caramelization and a Maillard reaction by heat is preferable for maintaining excellent injection moldability and excellent extrudability and printability during the three-dimensional molding.
  • the sugar alcohol may have a glass transition temperature of a room temperature (1 to 30° C.) or higher, preferably 40° C. or higher, according to the Japanese Pharmacopoeia, Sixteenth Edition.
  • the “water-soluble sugar and/or water-soluble sugar alcohol” is desirably one or more kinds of sugar alcohols selected from the group consisting of maltitol, xylitol, mannitol, erythritol, sorbitol, isomalt, and lactitol, preferably one or more kinds of sugar alcohols selected from the group consisting of maltitol, isomalt, and lactitol. Maltitol is more preferable.
  • the water-soluble sugar and/or the water-soluble sugar alcohol may be changed without being particularly limited to the above within a range capable of achieving the effect of the present invention.
  • sucrose or the like may be used as the sugar.
  • the content of the water-soluble sugar and/or the water-soluble sugar alcohol is 10 to 65 wt. %, preferably 10 to 60 wt. %, more preferably 20 to 65 wt. %, further preferably 20 to 60 wt. %, particularly preferably 35 to 55 wt. %, particularly preferably 20 to 55 wt. %, with respect to the total weight of the material for three-dimensionally molded object (the filament for three-dimensionally molded object, the three-dimensionally molded object).
  • the content may be changed without a particular limitation within a range capable of achieving the effect of the present invention.
  • plasticizer component refers to a component serving as a plasticizer in the filament for three-dimensionally molded object and the three-dimensionally molded object, and the plasticizer component is added to maintain excellent injection moldability and printability.
  • the plasticizer is desirably one or more kinds selected from the group consisting of triethyl citrate, macrogol, triacetin, a medium-chain fatty acid triglyceride, a polyoxyethylene polyoxypropylene block copolymer, and castor oil.
  • Triethyl citrate is preferable.
  • plasticizer component may be changed without being particularly limited to the above within a range capable of achieving the effect of the present invention.
  • the content of the plasticizer component is 1 to 30 wt. %, preferably 1 to 10 wt. %, more preferably 1 to 5 wt. %, with respect to the total weight of the material for three-dimensionally molded object (the three-dimensionally molded object).
  • the content may be changed without a particular limitation within a range capable of achieving the effect of the present invention.
  • the present invention is not particularly limited to the present production method.
  • a material mixing step in which the water-soluble thermoplastic polymer, the active component, the water-soluble sugar and/or the water-soluble sugar alcohol, and the plasticizer component are mixed to obtain the material for three-dimensionally molded object;
  • a filament producing step in which the material for three-dimensionally molded object, which has been compressed and melt-kneaded, is subjected to injection molding, and then wound up with a winder to produce the filament;
  • a molding step in which the filament is thermally melted, extruded from a nozzle, and laminated on a molding stage to mold the three-dimensionally molded object.
  • the active component, the water-soluble thermoplastic polymer, the water-soluble sugar and/or the water-soluble sugar alcohol, and the plasticizer component are each mixed in a predetermined formulation ratio using a mixer to obtain the material for three-dimensionally molded object.
  • the material for three-dimensionally molded object thus obtained is melt-kneaded while been compressed under a predetermined pressure using a known extruding machine (e.g., an extruder) in the compressing and melt-kneading step.
  • a known extruding machine e.g., an extruder
  • injection molding is performed using a molder and an injection-molded object is wound up with an automatic winder to obtain the filament for three-dimensionally molded object in the filament producing step.
  • a melting temperature is set to 120 to 200° C., preferably 140 to 170° C., for suitably melt-kneading the material for three-dimensionally molded object in the extruding machine. Further, it is desirable that the rotation number of barrel is increased to 100 to 200 rpm during kneading and decreased to 5 to 30 rpm during injection molding. Further, it is desirable that melt-kneading time is set to 3 to 15 minutes.
  • the filament for three-dimensionally molded object thus obtained is thermally melted, extruded from a nozzle, and molded while being laminated on a molding stage using a known fused deposition modeling type 3D printing apparatus to obtain the three-dimensionally molded object.
  • a nozzle temperature is set to 80 to 250° C., preferably 110 to 200° C., more preferably 150° C. or 160° C. or higher and 250° C. or 200° C. or lower, for suitably extruding the filament for three-dimensionally molded object from the nozzle.
  • the three-dimensionally molded object is produced by using the material for three-dimensionally molded object (the filament for three-dimensionally molded object) of the present invention, it becomes possible to form the solid object that exhibits excellent injection moldability and printability (plasticity) as well as fast elutability adjusted to increase the elution rate of the pharmaceutically active component.
  • the term “injection moldability” will be described.
  • the filament for three-dimensionally molded object needs to be molded into a fixed thickness.
  • a reason for this is that if a diameter of the molded filament is uneven, an extrusion amount from the 3D printing apparatus becomes uneven, thereby easily causing a printing failure.
  • the filament needs to be solidified relatively quickly. A reason for this is that the slow solidification results in the filament of uneven thickness.
  • the term “printability” will be described.
  • the filament for three-dimensionally molded object needs to be inserted into a silicon tube attached to the 3D printing apparatus for setting the filament to the 3D printing apparatus.
  • This operation requires the filament to be flexible enough to be bent to some extent (the filament can be set to the apparatus if the filament is bendable at least when heated). Further, the filament needs to have enough plasticity not to be broken when it is suitably bent to be set to the apparatus.
  • a reason for this is that if the filament has low plasticity and is thus fragile, a part of the filament is chipped, thereby causing a gap, which makes it difficult to perform stable printing. Further, after the filament is melted at a tip of the nozzle of the 3D printing apparatus, a melted material needs to be extruded by a fixed amount.
  • Using the material for three-dimensionally molded object of the present invention gives a good result in injection moldability and printability and makes it possible to form a desired three-dimensionally molded object.
  • the elution rate of the active component in the solid object is 80% or higher within 120 minutes, preferably 80% or higher within 85 minutes, more preferably 80% or higher within 60 minutes, further preferably 80% or higher within 30 minutes, particularly preferably 85% or higher within 30 minutes, particularly preferably 90% or higher within 30 minutes, particularly preferably 85% or higher within 15 minutes.
  • An upper limit of the elution rate is 100%.
  • a test solution used in the dissolution test for example, a dissolution test 1st fluid, water, or the like may be used.
  • Using the material for three-dimensionally molded object of the present invention makes it possible to form a fast-eluting solid object that quickly elutes the active component.
  • a filament was prepared using a material for three-dimensionally molded object having a formulation ratio shown in Table 1 with a extruder equipped with an injection molder, Xplore (registered trademark, manufactured by DSM) and then a solid object serving as a three-dimensionally molded object was produced using a fused deposition modeling type 3D printing apparatus, Eagleed (registered trademark, manufactured by Reis Enterprise Co., Ltd).
  • N 2 -[(2E)-3-(4-chlorophenyl)-2-propenoyl]-N-[2-oxo-2-(4- ⁇ [6-(trifluoromethyl)pyrimidine-4-yl]oxy ⁇ piperidine-1-yl)ethyl]-3-pyridine-2-yl-L-alaninamide manufactured by Astellas Pharma Inc., a solubility to a dissolution test 1st fluid of the Japanese Pharmacopoeia: >100 ⁇ M, a solubility to a dissolution test 2nd fluid of the Japanese Pharmacopoeia: 23.2 ⁇ M, hereinafter abbreviated as a compound A
  • Poly(vinyl alcohol) [MW 6000] manufactured by Polysciences, Inc., the same hereinafter unless otherwise specified
  • Each solid object in Examples 1-1 and 1-2 and Comparative example 1-1 was formed in a cylinder shape, and setting values of 3D CAD data were set such that height of each solid object became 1.5 mm and a diameter of each solid object became 12.0 mm.
  • a test liquid As a test liquid, 900 ml of the dissolution test 1st fluid was used and an elution rate of the active component (the compound A) after starting the test was evaluated by an ultraviolet-visible spectroscopic method (a UV-VIS method).
  • a UV-VIS method an ultraviolet-visible spectroscopic method
  • a graph in FIG. 1 shows a relation between “time (min) after starting test” and “elution rate (%) of active component” of the solid object in each Example.
  • Example 1-1 showed an average elution rate of 87.9% after the lapse of 55 minutes.
  • Example 1-2 The solid object in Example 1-2 showed an average elution rate of 87.5% after the lapse of 45 minutes.
  • a formulation ratio of each constituent component was adjusted such that the compound A as the active component became 20 wt. %, the polyvinyl alcohol became 20 wt. %, maltitol became 55 wt. %, and triethyl citrate became 5 wt. % with respect to 100 wt. % of the total weight.
  • the elution test was performed using the solid objects in Examples 2-1 to 2-3 in the same manner as in Test example 1 in accordance with the paddle method (the paddle rotation number: 50 rpm) of the dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition.
  • a graph in FIG. 3 shows a relation between the “time (min) after starting test” and the “elution rate (%) of active component” of the solid object in each of Examples 2-1 to 2-3.
  • the solid object formed in the cylinder shape in Example 2-1 showed the average elution rate of 87.5% after the lapse of 45 minutes
  • the solid object formed in the ring shape 1 in Example 2-2 showed the average elution rate of 95.3% after the lapse of 20 minutes
  • the solid object formed in the ring shape 2 in Example 2-3 showed the average elution rate of 94.1% after the lapse of 10 minutes.
  • Example 3 As the three-dimensionally molded object including 100 mg of the active component, the solid object in Example 3 having a shape and a formulation ratio shown in Table 3 was produced.
  • the ring shape 1 shown in FIG. 2B was selected as the shape in Example 3 and a formulation ratio of each constituent component was adjusted such that the compound A as the active component became 20 wt. %, the polyvinyl alcohol became 20 wt. %, maltitol became 55 wt. %, and triethyl citrate became 5 wt. % with respect to 100 wt. % of the total weight.
  • the elution test was performed using the solid object in Example 3 shown in Table 3 in the same manner as in Test example 1 in accordance with the paddle method (the paddle rotation number: 50 rpm) of the dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition.
  • a graph in FIG. 4 shows a relation between the “time (min) after starting test” and the “elution rate (%) of active component” of the solid object in Example 3.
  • Example 3 From the results in Test example 3, the solid object in Example 3 showed the elution rate of 92.0% after the lapse of 20 minutes.
  • a test for evaluating oral absorbability in a dog was performed using the solid object in Example 3.
  • the dogs were fasted from 16 hours before administration of the solid object in Example 3 until completion of the blood collection at 8 hours after administration of the solid object. Further, the dogs were restricted from water from 30 minutes before administration until completion of the blood collection at 2 hours after administration.
  • intramuscular administration of pentagastrin (0.015 mg/kg) was performed at 30 minutes before administration of the solid object in Example 3, and 30 and 90 minutes after administration of the solid object.
  • water is administered by a catheter immediately after administration of the solid object to obtain a total administration liquid amount of up to 50 ml.
  • a graph in FIG. 5 shows a relation between “time (h) after oral administration” and “concentration in blood plasma ( ⁇ g/ml)” of the solid object in Example 3.
  • Cmax ( ⁇ g/ml) represents a maximum concentration in the blood plasma and “Tmax (h)” represents a time required for reaching the maximum concentration in the blood plasma (a time required for reaching Cmax).
  • AUC 0-24 ( ⁇ g ⁇ h/ml) represents an area under the blood plasma drug concentration-time curve from the time of oral administration to 24 hours after oral administration.
  • Example 3 Tmax was 1.2 ⁇ 0.8 (h) and AUC was 35.1 ⁇ 11.1 ( ⁇ g ⁇ h/ml), thus it could be said that the solid object of the present invention exhibited a performance of quickly releasing a drug in vivo.
  • the ring shape 1 shown in FIG. 2B was selected as the shape in Examples 4-1 to 4-8 and printing was performed on the basis of 3D CAD data in which an outer diameter of the ring was set to 12.0 mm and an inner diameter of the ring was set to 7.6 mm.
  • a formulation ratio of each constituent component was adjusted such that the compound A as the active component became 20 wt. %, the polyvinyl alcohol became 40 wt. %, the water-soluble sugar and/or the water-soluble sugar alcohol became 35 wt. %, and triethyl citrate became 5 wt. % with respect to 100 wt. % of the total weight.
  • xylitol product name: xylitol, manufactured by Wako Pure Chemical Industries, Ltd.
  • mannitol product name: Pearlitol 200SD, manufactured by Roquette
  • lactitol product name: lactitol monohydrate, manufactured by Wako Pure Chemical Industries, Ltd.
  • sucrose product name: sucrose, manufactured by Wako Pure Chemical Industries, Ltd.
  • erythritol product name: erythritol 100M, manufactured by B Food Science Co., Ltd.
  • sorbitol product name: sorbitol, manufactured by KANTO CHEMICAL Co., Inc.
  • isomalt product name: Galen IQ720, manufactured by BENEO-Palatinit GmbH
  • the elution test was performed using the solid objects in Examples 4-1 to 4-8 in the same manner as in Test example 1 in accordance with the paddle method (the paddle rotation number: 50 rpm) of the dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition.
  • a graph in FIG. 6 shows a relation between the “time (min) after starting test” and the “elution rate (%) of active component” of the solid object in each of Examples 4-1 to 4-8.
  • Example 4-1 maltitol
  • Example 4-2 xylitol
  • Example 4-3 mannitol
  • Example 4-4 lactitol
  • Example 4-5 sucrose
  • Example 4-6 erythritol
  • Example 4-7 sorbitol
  • 92% isomalt
  • Example 5-1 acetaminophen (product name: pharmacopoeia acetaminophen, manufactured by YAMAMOTO Corp.) was formulated as the active component and, in Example 5-2, theophylline (product name: Theophylline, manufactured by Tokyo Chemical Industry Co., Ltd.) was formulated as the active component.
  • acetaminophen product name: pharmacopoeia acetaminophen, manufactured by YAMAMOTO Corp.
  • Example 5-2 theophylline (product name: Theophylline, manufactured by Tokyo Chemical Industry Co., Ltd.) was formulated as the active component.
  • the ring shape 1 shown in FIG. 2B was selected as the shape in Examples 5-1 and 5-2 and printing was performed on the basis of 3D CAD data in which an outer diameter of the ring was set to 12.0 mm and an inner diameter of the ring was set to 7.6 mm.
  • a formulation ratio of each constituent component was adjusted such that the active component became 20 wt. %, the polyvinyl alcohol became 40 wt. %, maltitol became 35 wt. %, and triethyl citrate became 5 wt. % with respect to 100 wt. % of the total weight.
  • the elution test was performed using the solid objects in Examples 5-1 and 5-2 in the same manner as in Test example 1 in accordance with the paddle method (the paddle rotation number: 50 rpm) of the dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition.
  • a graph in FIG. 7 shows a relation between the “time (min) after starting test” and the “elution rate (%) of active component” of the solid object in each of Examples 5-1 and 5-2.
  • the ring shape 1 shown in FIG. 2B was selected as the shape in Comparative examples 2-1 and 2-2 and printing was performed on the basis of 3D CAD data in which an outer diameter of the ring was set to 12.0 mm and an inner diameter of the ring was set to 7.6 mm.
  • a formulation ratio of each constituent component was adjusted such that the compound A as the active component became 20 wt. %, the polyvinyl alcohol became 40 wt. %, tricalcium phosphate (product name: tricalcium phosphate food additives, manufactured by KANTO CHEMICAL Co., Inc.) or talc (product name: crown talc pharmacopoeia PP, manufactured by matsumura sangyo Co., Ltd.) became 35 wt. %, and triethyl citrate became 5 wt. % with respect to 100 wt. % of the total weight.
  • the elution test was performed using the solid objects in Comparative examples 2-1 and 2-2 shown in Table 7 in the same manner as in Test example 1 in accordance with the paddle method (the paddle rotation number: 50 rpm) of the dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition.
  • a graph in FIG. 8 shows a relation between the “time (min) after starting test” and the “elution rate (%) of active component” of the solid object in each of Comparative examples 2-1 and 2-2.
  • Comparative examples 2-1 and 2-2 showed the elution rates after the lapse of 30 minutes of 63% (Comparative example 2-1: tricalcium phosphate) and 60% (Comparative example 2-2: talc), both values being lower than 80%.
  • the ring shape 1 shown in FIG. 2B was selected as the shape in Example 6 and printing was performed on the basis of 3D CAD data in which an outer diameter of the ring was set to 12.0 mm and an inner diameter of the ring was set to 7.6 mm.
  • a formulation ratio of each constituent component was adjusted such that the compound A as the active component became 20 wt. %, the polyvinyl alcohol became 55 wt. %, maltitol became 20 wt. %, and triethyl citrate became 5 wt. % with respect to 100 wt. % of the total weight.
  • the elution test was performed using the solid object in Example 6 shown in Table 8 in the same manner as in Test example 1 in accordance with the paddle method (the paddle rotation number: 50 rpm) of the dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition.
  • a graph in FIG. 9 shows a relation between the “time (min) after starting test” and the “elution rate (%) of active component” of the solid object in Example 6.
  • Example 6 showed the elution rate after the lapse of 30 minutes of 80%. It was found that the elution rate increased by an increase in the addition amount of maltitol by comparing the elution rates obtained with the above formulation, the formulation in Example 2-2 in which maltitol was added in the amount of 55 wt. %, and the formulation in Example 4-1 in which maltitol was added in the amount of 35 wt. %.
  • the filaments in Examples 7-1 and 7-2 having formulation and formulation ratios shown in Table 9 were produced by selecting polyvinylpyrrolidone (Polyvinylpyrrolidone [Mw40000], manufactured by Sigma Aldrich) or aminoalkyl methacrylate copolymer E (Eudragit EPO, manufactured by Evonik Industries AG) instead of the polyvinyl alcohol as the thermoplastic polymer.
  • a formulation ratio of each constituent component was adjusted such that the compound A as the active component became 20 wt. %, the thermoplastic polymer became 40 wt. %, maltitol became 35 wt. %, and triethyl citrate became 5 wt. % with respect to 100 wt. % of the total weight.
  • the filament produced by using polyvinylpyrrolidone tended to be more fragile as compared to the one produced by using the polyvinyl alcohol.
  • EXAMPLE 7-2 AMINOALKYL EXAMPLE 7-1 METHACRYLATE POLYVINYLPYRROLIDONE COPOLYMER E EACH COMPOUND A 20 20 CONSTITUENT POLYVINYLPYRROLIDONE 40 — COMPONENT AMINOALKYL METHACRYLATE — 40 (wt. %) COPOLYMER E MALTITOL 35 35 TRIETHYL CITRATE 5 5
  • the elution test was performed using the filaments in Examples 7-1 and 7-2 shown in Table 9, the filament including the polyvinyl alcohol and maltitol produced in Example 4-1, and the filament including the polyvinyl alcohol and tricalcium phosphate produced in Comparative example 2-1 in the same manner as in Test example 1 in accordance with the paddle method (the paddle rotation number: 50 rpm) of the dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition.
  • each filament in use included the compound A having a weight of 50 mg as the active component.
  • a graph in FIG. 10 shows a relation between the “time (min) after starting test” and the “elution rate (%) of active component” of the filament in each of Examples 4-1, 7-1, and 7-2, and Comparative example 2-1.
  • Example 7-1 polyvinylpyrrolidone
  • Example 7-2 aminoalkyl methacrylate copolymer E
  • the filament including the polyvinyl alcohol and maltitol in Example 4-1 and the filament including the polyvinyl alcohol and tricalcium phosphate in Comparative example 2-1 had the elution rates after the lapse of 5 minutes of 44% and 25%, respectively, thus it was found that the fast elutability was exhibited in the formulation in Examples 7-1 and 7-2 in which polyvinylpyrrolidone and aminoalkyl methacrylate copolymer E were used.
  • Example 7-1 Three-Dimensionally Molded Object Using Polyvinylpyrrolidone
  • the ring shape 1 shown in FIG. 2B was selected as the shape of the solid object in Example 7-1 and printing was performed on the basis of 3D CAD data in which an outer diameter of the ring was set to 12.0 mm and an inner diameter of the ring was set to 7.6 mm.
  • a weight of a printed object and a height of the solid object were shown in Table 10.
  • the elution test was performed using the solid object in Example 7-1 in the same manner as in Test example 1 in accordance with the paddle method (the paddle rotation number: 50 rpm) of the dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition.
  • a graph in FIG. 11 shows a relation between the “time (min) after starting test” and the “elution rate (%) of active component” of the solid object in Example 7-1.
  • FIG. 11 also showed the graph of the solid object in Example 4-1.
  • Example 7-1 showed the elution rate after the lapse of 30 minutes of 99%.
  • the three-dimensionally molded object of the present invention can be suitably used as various molded objects for a pharmaceutical agent, a quasi-drug, a health food, a food for specified health uses, a food with nutrient function claims, a food with function claims, and a supplement, and thus has an industrial applicability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Mechanical Engineering (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US16/088,041 2016-04-06 2017-04-05 Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object Abandoned US20190217531A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016076810 2016-04-06
JP2016-076810 2016-04-06
PCT/JP2017/014205 WO2017175792A1 (fr) 2016-04-06 2017-04-05 Moulage tridimensionnel à élution rapide, filament pour moulage tridimensionnel à élution rapide et matériau pour moulage tridimensionnel à élution rapide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/014205 A-371-Of-International WO2017175792A1 (fr) 2016-04-06 2017-04-05 Moulage tridimensionnel à élution rapide, filament pour moulage tridimensionnel à élution rapide et matériau pour moulage tridimensionnel à élution rapide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/113,482 Continuation US12377601B2 (en) 2016-04-06 2023-02-23 Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object

Publications (1)

Publication Number Publication Date
US20190217531A1 true US20190217531A1 (en) 2019-07-18

Family

ID=60001250

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/088,041 Abandoned US20190217531A1 (en) 2016-04-06 2017-04-05 Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object
US18/113,482 Active 2037-04-27 US12377601B2 (en) 2016-04-06 2023-02-23 Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/113,482 Active 2037-04-27 US12377601B2 (en) 2016-04-06 2023-02-23 Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object

Country Status (5)

Country Link
US (2) US20190217531A1 (fr)
EP (1) EP3441065B1 (fr)
JP (2) JPWO2017175792A1 (fr)
ES (1) ES2992002T3 (fr)
WO (1) WO2017175792A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12043730B2 (en) 2018-07-30 2024-07-23 Mitsubishi Chemical Corporation Fused deposition modeling type additive manufacturing material
US12247071B2 (en) 2016-12-21 2025-03-11 Amgen Inc. Anti-TNF alpha antibody formulations
US12377601B2 (en) 2016-04-06 2025-08-05 Astellas Pharma Inc. Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3590501A1 (fr) * 2018-07-06 2020-01-08 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Procédé et système de fabrication d'un produit d'administration de médicament imprimé en 3d
WO2020041376A1 (fr) * 2018-08-20 2020-02-27 Vanderbilt University Filament d'imprimante fdm thermosensible pour former des canaux vasculaires dans des hydrogels
JP7238509B2 (ja) * 2019-03-19 2023-03-14 三菱ケミカル株式会社 医薬錠剤
JP2025115978A (ja) * 2024-01-26 2025-08-07 富士化学工業株式会社 徐放性製剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004026750A (ja) * 2002-06-27 2004-01-29 Nippon Shinyaku Co Ltd 薬物の安定化法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51127068A (en) 1975-04-26 1976-11-05 Tanabe Seiyaku Co Ltd A process for preparing 8-azaprostanoic acid derivatives.
DE19536394A1 (de) 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
ATE421318T1 (de) * 1997-02-20 2009-02-15 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
JP3626483B2 (ja) * 2001-05-10 2005-03-09 山之内製薬株式会社 口腔内速崩壊性錠剤およびその製造法
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
US20090004284A1 (en) 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
JP5615554B2 (ja) * 2007-11-27 2014-10-29 富山化学工業株式会社 ３−｛５−［４−（シクロペンチルオキシ）−２−ヒドロキシベンゾイル］−２−［（３−ヒドロキシ−１，２−ベンズイソオキサゾール−６−イル）メトキシ］フェニル｝プロピオン酸またはその塩を含有する固体分散体の組成物
CA2776164C (fr) 2009-10-01 2016-12-13 Aptalis Pharmatech, Inc. Compositions de corticosteroides administrees par voie orale
JP2013523634A (ja) * 2010-03-26 2013-06-17 ダウ グローバル テクノロジーズ エルエルシー 溶融押出フィルム
KR20140006879A (ko) 2011-02-17 2014-01-16 에프. 호프만-라 로슈 아게 고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법
ES2761407T3 (es) * 2013-03-15 2020-05-19 Aprecia Pharmaceuticals LLC Forma de dosificación rápidamente dispersable de topiramato
US10179853B2 (en) 2013-09-11 2019-01-15 Toray Industries, Inc. Material for fused deposition modeling type three-dimensional modeling, and filament for fused deposition modeling type 3D printing device
US20160066601A1 (en) 2014-09-06 2016-03-10 Ashley G. Herr Edible 3d printer filament
CN114670437B (zh) * 2014-09-08 2025-10-31 兰开夏大学 固体剂型生产
EP3441065B1 (fr) 2016-04-06 2024-10-09 Astellas Pharma Inc. Moulage tridimensionnel à élution rapide, filament pour moulage tridimensionnel à élution rapide et matériau pour moulage tridimensionnel à élution rapide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004026750A (ja) * 2002-06-27 2004-01-29 Nippon Shinyaku Co Ltd 薬物の安定化法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377601B2 (en) 2016-04-06 2025-08-05 Astellas Pharma Inc. Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object
US12247071B2 (en) 2016-12-21 2025-03-11 Amgen Inc. Anti-TNF alpha antibody formulations
US12043730B2 (en) 2018-07-30 2024-07-23 Mitsubishi Chemical Corporation Fused deposition modeling type additive manufacturing material

Also Published As

Publication number Publication date
US12377601B2 (en) 2025-08-05
JP2021193147A (ja) 2021-12-23
EP3441065A1 (fr) 2019-02-13
EP3441065A4 (fr) 2019-11-20
EP3441065C0 (fr) 2024-10-09
ES2992002T3 (es) 2024-12-05
US20230202096A1 (en) 2023-06-29
JP7127725B2 (ja) 2022-08-30
JPWO2017175792A1 (ja) 2019-02-14
EP3441065B1 (fr) 2024-10-09
WO2017175792A1 (fr) 2017-10-12

Similar Documents

Publication Publication Date Title
US12377601B2 (en) Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object
KR101116518B1 (ko) 다중입자
JP5443344B2 (ja) タダラフィルを含む薬剤の製造の方法
JP6022410B2 (ja) 低置換度ヒドロキシプロピルセルロースを含む複合造粒物の製造方法
US20120244197A1 (en) Film-Like Pharmaceutical Dosage Forms
WO2022121927A1 (fr) Formes galéniques orales à libération prolongée retardée d'un inhibiteur de janus kinase (jak) et leurs méthodes d'utilisation
CN105873572A (zh) 包含药理学活性成分的口腔崩解多孔膜及其制备方法
Feng et al. Twin-screw extrusion of sustained-release oral dosage forms and medical implants
JP2015117240A (ja) 複合造粒物及び速放性錠剤並びにこれらの製造方法
US20190015343A1 (en) Combination of drugs having different potency
CN106692091A (zh) 一种3d打印胃漂浮制剂及其制备方法
CN101820866B (zh) 用于固体剂型的机械保护层
US20100221335A1 (en) Sustained-release preparation and method for producing the same
JP2016507579A (ja) 経口投与用の咀嚼可能な組成物およびその製造方法
EP2486917A1 (fr) Film de revêtement, et granulés ainsi que comprimés mettant en uvre celui-ci
KR102589344B1 (ko) 산 민감성 성분을 포함하는 삼투성 제제 조성물
EP2238974A1 (fr) Granulé pour la formulation de comprimés orodispersibles
KR102153894B1 (ko) 온단세트론 또는 이의 염을 함유하는 구강 붕해형 필름 제제 및 이의 제조방법
KR100542473B1 (ko) 페린도프릴의 조절 방출을 위한 열성형가능한 고체 약제조성물
EP3895691A1 (fr) Otf d'acétate d'ulipristal
EP4366706B1 (fr) Matériaux imprimables à base d'amidon
US20240245621A1 (en) Method for producing a core-shell capsule for delivering a therapeutic agent
EP4115877A1 (fr) Matériaux imprimables à base d'amidon
JP2023146845A (ja) 三次元造形物の製造方法
KR20240164192A (ko) 사이클로스포린의 속효성 3d 프린트 정제의 조성 및 제조 방법

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTELLAS PHARMA INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IKEDA, SORATO;HATTORI, SHOTA;KOBAYASHI, MASANORI;SIGNING DATES FROM 20180823 TO 20180828;REEL/FRAME:046966/0921

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION